Loading...
A200230 logo

TELCON RF PHARMACEUTICAL. Inc.KOSDAQ:A200230 Stock Report

Market Cap ₩14.9b
Share Price
n/a
1Y-82.7%
7D-3.8%
1D-1.8%
Portfolio Value
​
View

TELCON RF PHARMACEUTICAL. Inc.

KOSDAQ:A200230 Stock Report

Market Cap: ₩14.9b

TELCON RF PHARMACEUTICAL (A200230) Stock Overview

Primarily engages in the development, production, and sale of RF coaxial connectors worldwide. More details

A200230 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 14.7% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the KR market

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (₩15B)


A200230 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW435,612 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
435,612 investors already sharing narratives
View all narratives

TELCON RF PHARMACEUTICAL. Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TELCON RF PHARMACEUTICAL
Historical stock prices
Current Share Price₩2,140.00
52 Week High₩14,950.00
52 Week Low₩1,700.00
Beta0.41
1 Month Change-10.65%
3 Month Changen/a
1 Year Change-82.66%
3 Year Change-92.63%
5 Year Change-98.44%
Change since IPO-94.54%

Recent News & Updates

Recent updates

Analysis Article • Feb 05

Some Shareholders Feeling Restless Over TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) P/S Ratio

With a median price-to-sales (or "P/S") ratio of close to 0.9x in the Electronic industry in Korea, you could be...
Analysis Article • Dec 02

Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Sep 11

More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%

TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders won't be pleased to see that the share price has had a...
Analysis Article • Jul 22

TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With Revenues

TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shares have continued their recent momentum with a 35% gain in the...
Analysis Article • Mar 24

TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too Soon

There wouldn't be many who think TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of...
Analysis Article • Oct 23

TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing

When close to half the companies in the Electronic industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...
Analysis Article • Sep 06

TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Analysis Article • Mar 26

Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Earnings

TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...
Analysis Article • Mar 13

TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than Expected

TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of 2.4x may not look like an...
Analysis Article • Apr 05

Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Feb 03

Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?

TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders might be concerned after seeing the share price drop 20...

Shareholder Returns

A200230KR ElectronicKR Market
7D-3.8%2.3%7.1%
1Y-82.7%177.3%100.8%

Return vs Industry: A200230 underperformed the KR Electronic industry which returned 177.3% over the past year.

Return vs Market: A200230 underperformed the KR Market which returned 100.8% over the past year.

Price Volatility

Is A200230's price volatile compared to industry and market?
A200230 volatility
A200230 Average Weekly Movement17.4%
Electronic Industry Average Movement11.2%
Market Average Movement9.1%
10% most volatile stocks in KR Market16.5%
10% least volatile stocks in KR Market4.5%

Stable Share Price: A200230's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A200230's weekly volatility has increased from 12% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999125Jin-Hun Limwww.telcon.co.kr

TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals.

TELCON RF PHARMACEUTICAL. Inc. Fundamentals Summary

How do TELCON RF PHARMACEUTICAL's earnings and revenue compare to its market cap?
A200230 fundamental statistics
Market cap₩14.94b
Earnings (TTM)-₩15.75b
Revenue (TTM)₩61.78b
0.2x
P/S Ratio
-0.9x
P/E Ratio

Is A200230 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A200230 income statement (TTM)
Revenue₩61.78b
Cost of Revenue₩40.28b
Gross Profit₩21.50b
Other Expenses₩37.25b
Earnings-₩15.75b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.30k
Gross Margin34.80%
Net Profit Margin-25.49%
Debt/Equity Ratio58.5%

How did A200230 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 08:35
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TELCON RF PHARMACEUTICAL. Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang Ju ParkDaishin Securities Co. Ltd.